A Potassium Binder or a Lower ACE Inhibitor Dose
A proteinuric CKD patient's potassium has crept into dangerous territory on a proven, high-dose ACE inhibitor. The question isn't whether the hyperkalemia is real — it is — it's whether the right response is a second drug to manage it, or a smaller dose of the first one.
A potassium of 5.7 mEq/L on a routine metabolic panel is what brought J.M.'s case back to the team's attention this week. He is a 55-year-old man who has supervised the same warehouse loading dock for nineteen years, work he says keeps him "on his feet enough not to think about" the type 2 diabetes he's managed for a decade. His diabetic nephropathy was caught early through routine screening, and his lisinopril was pushed to 40mg daily over eighteen months specifically because his UACR kept falling as the dose rose — from 890 mg/g at diagnosis to 310 mg/g at his last visit, real, dose-tracked proteinuria benefit, not an assumption. Today's routine metabolic panel came back with a potassium of 5.7 mEq/L, up from 4.8 three months ago, with no acute illness, no NSAID use, and no dietary change he can identify.
The reflex in this situation has always been to back off the drug that's driving the potassium up. OPAL-HK tested a different answer directly: in CKD patients with hyperkalemia already on RAAS inhibitor therapy, patiromer allowed significantly more patients to remain normokalemic and on their RAASi at eight weeks than placebo did — the binder didn't just lower potassium, it let people keep the drug producing the proteinuria benefit they were on it for in the first place. J.M.'s own 65% reduction in albuminuria since the dose reached 40mg is precisely the kind of gain that reflexive dose reduction would put at risk without OPAL-HK's specific evidence that there's another way to hold the line.
Reviewing a potassium of 5.7 against a proteinuria response worth protecting
Add patiromer and hold lisinopril at 40mg. OPAL-HK is not a general hyperkalemia trial — it specifically enrolled CKD patients already on RAAS inhibitor therapy with elevated potassium, and found the binder let significantly more patients remain both normokalemic and on their RAASi at eight weeks. J.M.'s UACR has fallen from 890 to 310 tracking the dose upward — that's a real, measured response, not a theoretical benefit we'd be protecting on faith.
I don't dispute the proteinuria numbers, but 5.7 is a real value, not a borderline one, and adding a chronic daily binder — with its own GI tolerability issues and another prescription for a patient already juggling three medications — to keep a dose maxed out feels like treating the drug's side effect instead of the drug. A step down to 20 or 30mg likely still slows progression meaningfully, with less to manage going forward.
OPAL-HK shows the binder works, I agree — my hesitation is whether it should be reached for before a simpler option, dose reduction, is tried first.
These don't have to be sequential options. OPAL-HK's own protocol never required patients to be at maximum RAASi dose for the binder to show benefit — nothing in that trial argues against combining a modest reduction with patiromer rather than picking one lever. A step to 30mg alongside the binder gives two independent margins against recurrence instead of asking either intervention to carry the whole risk on its own, while still preserving most of the proteinuria gain J.M. has already made.
Agreed: patiromer started, lisinopril reduced to 30mg rather than stopped, potassium rechecked at one and four weeks to confirm both changes are working together rather than assuming either one alone would have been enough.
Not addressed today: whether patiromer will need to continue indefinitely or could eventually be weaned if the dose reduction alone proves sufficient at follow-up — left as a question for the one-month recheck rather than decided now.